ReviewCurrent opinion in neurobiology2024
Novel therapeutics in development for the treatment of stimulant-use disorder.
Review in Current opinion in neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The association between sleep disturbance and stimulant use: A cross-lagged examination.Addiction (Abingdon, England) · 2026Article
- The Phase-Amplitude Coupling Induced by Drug Cues in Individuals With Methamphetamine Use Disorder During Withdrawal.Brain and behavior · 2026Article
- Changes in Stimulant Use Over Time Among Men Who Have Sex with Men in Philadelphia, Baltimore, and Washington, DC, 2008-2023.AIDS and behavior · 2026Article
- Treating addiction with an addictive drug: the ketamine paradox revisited.Frontiers in psychiatry · 2026Review
- Review
- Ayahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice.Psychopharmacology · 2025Article
- Non-muscle myosin II is a promising therapeutic target.Trends in pharmacological sciences · 2025Article
- Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights.Pharmaceutics · 2025Review
- Article
- Socio-ecological Determinants of Detectable Viremia among Pregnant People Living with HIV in South Brazil: The Role of Stimulant Use Disorder and Homelessness.AIDS and behavior · 2025Article
- Severity of stimulant use disorder by psychostimulant type and polystimulant use pattern.Experimental and clinical psychopharmacology · 2025Article
- Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal.Addiction (Abingdon, England) · 2025Article
- Wellness-enhanced contingency management for stimulant use: A formative qualitative study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These stimulants include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, and prescription stimulants such as methylphenidate. Unlike opioids and alcohol, there are no therapies approved by the US Food and Drug Administration (FDA) to treat stimulant-use disorder. The high rate of relapse among this population highlights the insufficiency of current treatment options, which are limited to abstinence support programs and behavioral modification therapies. Here, we briefly outline recent regulatory actions taken by FDA to help support the development of new stimulant use disorder treatments and highlight several new therapeutics in the clinical development pipeline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.